Betamethasone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Betamethasone: From Autoimmune and Inflammatory Conditions to Alopecia Areata
One-Sentence Summary
Betamethasone is a synthetic glucocorticoid originally used for inflammatory and autoimmune conditions such as autoimmune disease, Crohn disease, adrenocortical insufficiency and skin disorders. The TxGNN model predicts it may be effective for Alopecia Areata, with 6 clinical trials (1 completed Phase 2) and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, inflammatory bowel disease (including Crohn disease), adrenocortical insufficiency, tinea pedis, exanthem (the New Zealand licence records contain no approved indication text) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| New Zealand Market Status | ✗ Cancelled only |
| Number of Authorizations | 9 (all cancelled) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Betamethasone is known to be a potent synthetic glucocorticoid receptor agonist with anti-inflammatory, antipruritic and vasoconstrictive activity. Its efficacy in inflammatory and autoimmune conditions is established.
Alopecia areata is a T-cell-mediated autoimmune disease in which the immune privilege of the hair follicle collapses, causing non-scarring hair loss. Corticosteroids suppress the inflammatory infiltrate around the follicle, so the mechanism is biologically plausible. Autoimmune disease is already among betamethasone's original indications. In practice, topical, intralesional and oral mini-pulse routes are all used.
Caveats: relapse after withdrawal is common, and long-term systemic steroid use carries a risk of adverse effects. Because all New Zealand licences are cancelled, formulation and availability need to be checked.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06786689 | Phase 2 | Completed | 60 | Weekly azathioprine pulse vs oral betamethasone mini-pulse in moderate to severe alopecia areata |
| NCT02350023 | Phase 4 | Completed | 50 | Topical latanoprost vs topical corticosteroid (betamethasone) in localized alopecia areata |
| NCT05803070 | N/A | Unknown | 59 | Topical cetirizine 1% vs topical betamethasone valerate 0.1% in localized alopecia areata |
| NCT06087796 | Phase 1 | Unknown | 60 | Topical pentoxifylline and metformin vs betamethasone valerate 0.1% cream in patchy alopecia areata |
| NCT07696585 | N/A | Not yet recruiting | 60 | Topical metformin 30%, simvastatin 2% and betamethasone valerate 0.1% in patchy alopecia areata; no results yet |
| NCT04207931 | Phase 4 | Recruiting | 250 | Treatment outcomes in central centrifugal cicatricial alopecia; a different disease, so only indirect relevance |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39393548 | 2025 | RCT | J Am Acad Dermatol | Microneedle transdermal delivery of compound betamethasone in alopecia areata, aiming to reduce the pain of intralesional injection |
| 40510104 | 2025 | RCT | Cureus | Oral cyclosporine vs oral betamethasone mini-pulse (n=60) |
| 34400956 | 2021 | RCT | Iran J Pharm Res | Oral pulse betamethasone, methotrexate and their combination in severe alopecia areata (double-blind, placebo-controlled, n=36) |
| 36257912 | 2022 | RCT | Dermatol Ther | Latanoprost vs minoxidil, betamethasone and combinations in alopecia areata |
| 32594786 | 2022 | RCT | J Dermatol Treat | Intralesional betamethasone vs triamcinolone acetonide in localized alopecia areata (within-patient design) |
| 37870096 | 2023 | Meta-analysis | Cochrane Database Syst Rev | Network meta-analysis of treatments for alopecia areata |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Efficacy, relapse and adverse effects of corticosteroid pulse therapy in alopecia areata |
| 38623137 | 2024 | Comparative study | Cureus | Topical betamethasone dipropionate vs topical minoxidil in alopecia areata |
| 40519428 | 2025 | Clinical study | Cureus | Efficacy and safety of oral betamethasone mini-pulses in moderate to severe alopecia areata |
| 17642661 | 2004 | Open uncontrolled study | Indian J Dermatol Venereol Leprol | Oral betamethasone mini-pulse therapy in extensive alopecia areata |
New Zealand Market Information
All 9 authorizations are cancelled and none are currently valid. No approved indication text is recorded. The main products are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 210870 | Diprosone | Cream 0.05% | Not recorded (cancelled) |
| 210897 | Diprosone | Ointment 0.05% | Not recorded (cancelled) |
| 2188759 | Beta Ointment | Ointment 0.1% | Not recorded (cancelled) |
| 512877 | Beta Scalp | Scalp application 0.1% | Not recorded (cancelled) |
| 2188740 | Beta Cream | Cream 0.1% | Not recorded (cancelled) |
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): hypertension, congestive heart failure, hyperglycemia, epilepsy, herpes simplex virus keratitis, measles, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, hyperargininemia, citrullinemia), and pituitary hormone deficiency conditions (e.g., hypopituitarism, Sheehan syndrome, Kallmann syndrome). These should be verified against the product label.
- Pharmacology: betamethasone acts as an agonist at the glucocorticoid receptor (NR3C1). No other drug interactions are recorded.
- Clinical caveats: long-term systemic steroid use carries a risk of adverse effects, and relapse after withdrawal is common.
Package insert warnings and contraindications were not available for this report, so please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 2 trial and several randomized studies (topical, intralesional and oral mini-pulse routes) support betamethasone in alopecia areata, and the mechanism is plausible for an autoimmune disease. However, the trials are small, mostly use betamethasone as a comparator, and no Phase 3 evidence is available. Also, all New Zealand licences are cancelled.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data
- Confirmation of currently available betamethasone formulations and routes in New Zealand
- Comparison with established alopecia areata options, and a plan for relapse and long-term steroid risk
- Verification of the knowledge-graph contraindications against the label
Other predictions: The remaining predicted indications are not recommended at this time. Alopecia mucinosa, telogen effluvium and folliculitis decalvans rest on case-level evidence only (Hold). Alopecia antibody deficiency, the genetic hair disorders and steroid-resistant nephrotic syndrome rest on model prediction alone (Hold). Idiopathic steroid-sensitive nephrotic syndrome has strong class-level support, but betamethasone evidence is limited to a 1981 pediatric report and prednisone or prednisolone remain the standard agents (research question only).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.